Hepalink (Hong Kong) Limited announced that it will receive $20 million in an equity round of funding from returning investor Shenzhen Hepalink Pharmaceutical Co., Ltd. on January 23, 2016. Post transaction, the investor will maintain its stake at 100% in the company. The transaction was approved at the 19th meeting of the 3rd directorate and 14th meeting of the 3rd supervisory board of the investor.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.47 CNY | -3.17% |
|
+14.51% | -19.27% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.27% | 1.78B | |
+25.40% | 45.35B | |
+38.38% | 24.34B | |
+27.09% | 16.51B | |
+21.19% | 14.6B | |
+71.91% | 14.27B | |
-0.05% | 6.79B | |
-11.63% | 6.57B | |
+15.08% | 5.76B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- 002399 Stock
- News Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
- Hepalink (Hong Kong) Limited announced that it expects to receive $20 million in funding from Shenzhen Hepalink Pharmaceutical Co., Ltd..